150 related articles for article (PubMed ID: 8548129)
1. Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma.
Segers K; Backhovens H; Singh SK; De Voecht J; Ramael M; Van Broeckhoven C; Van Marck E
Virchows Arch; 1995; 427(4):431-6. PubMed ID: 8548129
[TBL] [Abstract][Full Text] [Related]
2. Extrapleural solitary fibrous tumor: clinicopathologic study of 17 cases and molecular analysis of the p53 pathway.
Morimitsu Y; Nakajima M; Hisaoka M; Hashimoto H
APMIS; 2000 Sep; 108(9):617-25. PubMed ID: 11110050
[TBL] [Abstract][Full Text] [Related]
3. High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines.
Ungar S; Van de Meeren A; Tammilehto L; Linnainmaa K; Mattson K; Gerwin BI
Br J Cancer; 1996 Nov; 74(10):1534-40. PubMed ID: 8932331
[TBL] [Abstract][Full Text] [Related]
4. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
6. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma.
Soslow RA; Shen PU; Chung MH; Isacson C
Int J Gynecol Pathol; 1998 Apr; 17(2):129-34. PubMed ID: 9553809
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
8. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
[TBL] [Abstract][Full Text] [Related]
9. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium.
Ramael M; Lemmens G; Eerdekens C; Buysse C; Deblier I; Jacobs W; van Marck E
J Pathol; 1992 Dec; 168(4):371-5. PubMed ID: 1484318
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.
Koga T; Hashimoto S; Sugio K; Yoshino I; Nakagawa K; Yonemitsu Y; Sugimachi K; Sueishi K
Int J Cancer; 2001 Jul; 95(4):232-9. PubMed ID: 11400116
[TBL] [Abstract][Full Text] [Related]
11. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
12. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
13. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A
Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802
[TBL] [Abstract][Full Text] [Related]
14. p53 gene status and expression of p53, MDM2, and p14 proteins in ameloblastomas.
Kumamoto H; Izutsu T; Ohki K; Takahashi N; Ooya K
J Oral Pathol Med; 2004 May; 33(5):292-9. PubMed ID: 15078490
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Mdm2 expression in minor salivary gland tumours and its relationship to p53 gene status.
de Araújo VC; Martins MT; Leite KR; Gomez RS; de Araújo NS
Oral Oncol; 2000 Jan; 36(1):67-9. PubMed ID: 10889922
[TBL] [Abstract][Full Text] [Related]
16. Bivariate analysis of the p53 pathway to evaluate Ad-p53 gene therapy efficacy.
Jacobberger JW; Sramkoski RM; Zhang D; Zumstein LA; Doerksen LD; Merritt JA; Wright SA; Shults KE
Cytometry; 1999 Oct; 38(5):201-13. PubMed ID: 10516606
[TBL] [Abstract][Full Text] [Related]
17. Expression and mutation of the tumor suppressor gene p53 in AIDS-associated Kaposi's sarcoma.
Li JJ; Huang YQ; Cockerell CJ; Zhang WG; Nicolaides A; Friedman-Kien AE
Am J Dermatopathol; 1997 Aug; 19(4):373-8. PubMed ID: 9261472
[TBL] [Abstract][Full Text] [Related]
18. [Interaction between p53 and MDM2 in human lung cancer cells].
Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J
Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435
[TBL] [Abstract][Full Text] [Related]
19. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
Fulop V; Mok SC; Genest DR; Gati I; Doszpod J; Berkowitz RS
J Reprod Med; 1998 Feb; 43(2):119-27. PubMed ID: 9513873
[TBL] [Abstract][Full Text] [Related]
20. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.
Reifenberger G; Liu L; Ichimura K; Schmidt EE; Collins VP
Cancer Res; 1993 Jun; 53(12):2736-9. PubMed ID: 8504413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
